Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 3 of 3 results for bivalirudin

  1. Acute coronary syndromes (NG185)

    This guideline covers the early and longer-term (rehabilitation) management of acute coronary syndromes. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The guideline aims to improve survival and quality of life for people who have a heart attack or unstable angina.

    NICE guideline
    Published
    18 November 2020
    View recommendations

    Sections for NG185

  2. ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55)

    NICE has developed a medtech innovation briefing (MIB) on ClearWay RX for drug delivery to coronary artery thrombotic lesions

    Medtech innovation briefing
    Published
    11 March 2016

  3. Bivalirudin for the treatment of ST-segment-elevation myocardial infarction (TA230)

    This guideline has been updated and replaced by NICE guideline NG185.

    Technology appraisal guidance
    Published
    27 July 2011